Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT
NCT03793517Phase 3Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Sep 2018
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of decitabine in acute leukemia (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: Cumulative Incidence of Relapse at 2 years. Started Sep 2018; status: recruiting.
02
Drugs
decitabine
03
Conditions
acute leukemia
Beyond the preview
Go deeper on NCT03793517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03793517.